Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases-Reference-Cited by-同舟云学术

Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases

Published:2008-09 Issue:9 Volume:6 Page:1027-1035
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Wong Grace Lai–Hung,Wong Vincent Wai–Sun,Choi Paul Cheung–Lung,Chan Anthony Wing–Hung,Chum Richard Hoi–Leong,Chan Henry Kai–Wing,Lau Kenneth Ka–Ki,Chim Angel Mei–Ling,Yiu Karen Ka–Lam,Chan Francis Ka–Leung,Sung Joseph Jao–Yao,Chan Henry Lik–Yuen

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference41 articles.

1. Histological progression of nonalcoholic fatty liver disease in Chinese patients;Hui;Aliment Pharmacol Ther,2005

2. Metabolic and adipokine profile of Chinese patients with non-alcoholic fatty liver disease;Wong;Clin Gastroenterol Hepatol,2006

3. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update;Liaw;Liver Int,2005

4. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease;Rostom;Gastroenterology,2006

5. Chronic hepatitis B;Lok;Hepatology,2007

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment;Journal of Viral Hepatitis;2024-09-10

2. Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD: findings from NHANES (2017–2020);Lipids in Health and Disease;2024-02-07

3. Technical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis;Digestive Diseases and Sciences;2023-08-09

4. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase;Clinical and Molecular Hepatology;2023-04-01

5. Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience;JGH Open;2023-02-20